← board
PHGE
BiomX Ltddistress 8/10 · high distress / dilution risk$0.20-1%today-98% from 52w high
Respiratory 1
Lead: Chronic Pseudomonas Aeruginosa Infection
Revenue
pre-revenue
Liquidity
$1M
Runway
0.1 yrs
Shares 1y
-62%
Price & events
-94.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.3%
1D
-3.2%
1W
-56.6%
1M
-83.3%
3M
-95.0%
6M
-97.6%
1Y
-99.5%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $2.03M
- Volume
- 59.23K
- 52 Week Range
- $0.20 – $12.35
- Total Shares
- 10.15M
- Float Shares
- 7.88M
- Short %
- 7.89%
- % Held by Insiders
- 31.29%
- % Held by Institutions
- 3.37%
- RVOL
- 0.01x
- Beta
- 1.31
Pipeline stages · 1 programs
BX004
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-03 | Phase 2 | BX004 | Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF) | 63 | recruiting |
Catalyst news & presentations · 8
- 2026-08-12earningsEarningsEarnings releaseyahoo
- 2026-04-15partnershipFramework supply agreement with Israel Railways for AI-powered animal detection and deterrence alert stations.SEC 8-K
- 2026-04-13partnershipAcquired 100% of Mandragola's shareholdings in DFSL, a developer of LADAR-based detection systems.SEC 8-K
- 2026-04-10partnershipAcquisition of 100% of ZorroNet Ltd., an AI defense technology company, by BiomX Inc.SEC 8-K
- 2025-12-08trial discontinuedBX004 · BiomX discontinued the Phase 2b study of BX004 for cystic fibrosis due to resource constraints after DMC recommended continuation with adjusted dosing.SEC 8-K
- 2025-12-08trial discontinuedOngoing Phase 2b study discontinued due to resource constraintsSEC 8-K
- Q3 2025readoutPhase 2BX004 · Phase 2b resultsSEC 8-K
- Q1 2025readoutPhase 2BX211 · Phase 2 resultsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-03-09HC Wainwright & Co.Buy → Neutral
- 2025-11-26HC Wainwright & Co.Buy
- 2025-11-25HC Wainwright & Co.Buy
- 2025-08-20HC Wainwright & Co.Buy
- 2025-05-16HC Wainwright & Co.Buy
- 2025-04-04HC Wainwright & Co.Buy
Competitors — Chronic Pseudomonas Aeruginosa Infection
- none identified
Recent news
- 2026-07-19BiomX (PHGE) Stock Forum and Discussion - Moomoo
- 2026-07-17BiomX Inc. (NYSE: PHGE) seeks approval for Mandragola securities, $2M credit line and reverse split - Stock Titan
- 2026-07-15BiomX Inc. SEC Filing (Jul 15, 2026) - Stock Titan
- 2026-07-10BiomX cancels 1,013,637 conversion shares to regain NYSE American Section 712 compliance - TradingView
- 2026-07-10BiomX Dips on New Data Center - TradingView
- 2026-07-10BiomX: Zorronet Completes Transition to New Advanced Data Center Supporting Business Expansion and Enhanced AI Capabilities - Yahoo Finance UK
- 2026-07-09BiomX Company Profile & Introduction - Moomoo
- 2026-07-09BiomX (PHGE) Stock Soars Over 25% After-Hours: Here's Why it is Trending - Sahm
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.